Satisfaction with onychomycosis treatment: Pulse versus continuous dosing

Journal of the American Podiatric Medical Association

Volumn 93, Issue 1-6, 2003, Pages 373-379

  Warshaw, Erin M ^a,h   Bowman, Thomas ^b   Bodman, Myron A ^c,h   Kim, John J ^d,e   Silva, Stefanie ^f   Mathias, Susan D ^f,g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b North Oaks Podiatry   (United States)

^c Ohio College of Podiatric Medicine   (United States)

^d DUKE UNIVERSITY   (United States)

^e AMGEN INC   (United States)

^f IQVIA   (United States)

^g Ovation Research Group   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; ONYCHOMYCOSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVIEW; TELEPHONE; TREATMENT OUTCOME;

EID: 1842634530     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-93-5-373     Document Type: Review

References (19)

1. DRAKE LA, SCHER RK, SMITH EB, ET AL: Effect of onychomycosis on quality of life. J Am Acad Dermatol 38: 702, 1998.
2. SCHER RK: Onychomycosis: a significant medical disorder. J Am Acad Dermatol 35: S2, 1996.
3. SCHER RK: Onychomycosis is more than a cosmetic problem. Br J Dermatol 130 (suppl 43): 15, 1994.
4. RICH P, SCHEIN JR, LUBECK D: Onychomycosis: symptoms and quality of life associated with this medical condition [poster]. Presented at a meeting of the American Academy of Dermatology, July 31-August 4, 1998, Chicago.
5. LUBECK DP, GAUSE D, SCHEIN JR, ET AL: A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 8: 121, 1999.
6. DRAKE L: Quality of life issues for patients with fungal nail infections. AIDS Patient Care 9 (suppl 1): S15, 1995.
7. LUBECK DP: Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 38: S64, 1998.
8. ELEWSKI BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 11: 415, 1998.
9. COHEN PR, SCHER RK: Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 31: S74, 1994.
10. ARENAS R, DOMINGUEZ-CHERIT J, FERNÁNDEZ LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 34: 138, 1995.
11. BRÄUTIGAM M, NOLTING S, SCHOPF RE, ET AL: Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 311: 919, 1995.
12. DIMATTEO MR: Patient adherence to pharmacotherapy: the importance of effective communication. Formulary 30: 596, 1995.
13. HIRUMA M, MATSUSHITA A, KOBAYASHI M, ET AL: One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis: evaluation of treatment results according to patient background. Mycoses 44: 87, 2001.
14. GUPTA AK, DE DONCKER P, HANEKE E: Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 15: 112, 2000.
15. MORISKY DE, GREEN LW, LEVINE DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24: 67, 1986.
16. LOHR KN, AARONSON NK, ALONSO J, ET AL: Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 18: 979, 1996.
17. CRONBACH LJ: Coefficient alpha and the internal structure of tests. Psychometrika 16: 297, 1951.
18. Sporanox [package insert], Janssen Pharmaceutica, Inc, Titusville, NJ, 2001.
19. Lamisil [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ, 2001.